CN Patent

CN105188682A — 劳拉西泮的控释制剂

Assigned to EDGEMONT PHARMACEUTICALS LLC · Expires 2015-12-23 · 10y expired

What this patent protects

劳拉西泮的控释可以提供增强的施用选择，包括每天1次施用，其会在稳态条件下提供24小时治疗效果。所述药物组合物可以在药物溶出试验中提供基本上零级释放和在7-12小时内的90%释放。使用聚氧化乙烯作为基质聚合物，可以实现所述释放。

USPTO Abstract

劳拉西泮的控释可以提供增强的施用选择，包括每天1次施用，其会在稳态条件下提供24小时治疗效果。所述药物组合物可以在药物溶出试验中提供基本上零级释放和在7-12小时内的90%释放。使用聚氧化乙烯作为基质聚合物，可以实现所述释放。

Drugs covered by this patent

Patent Metadata

Patent number
CN105188682A
Jurisdiction
CN
Classification
—
Expires
2015-12-23
Drug substance claim
No
Drug product claim
No
Assignee
EDGEMONT PHARMACEUTICALS LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.